Flow Chart of NICE Study

Analysis on ITT population at study endpoints, compare data of each group

Randomization

Nimodipine treatment group n=328

Baseline: Evaluation within 7d after attack

Nimodipine (30mg,tid) and routine treatment for ischemic stroke

1 month follow-up: physical examination, commitment treatment record, safety evaluation, vascular dementia assessment

3 month follow-up: physical examination, laboratory examination, commitment treatment record, safety evaluation, vascular dementia assessment, MMSE, MoCA, ADAS-cog, FAB evaluation

6 month follow-up: physical examination, laboratory examination, commitment treatment record, safety evaluation, vascular dementia assessment, MMSE, MoCA, ADAS-cog, FAB evaluation, MRI (optional), ASPECTS or Fazekas or CHIPS evaluation (optional)

Adjust sample size

Control group n=328

Baseline: evaluation within 7d after attack

Placebo and routine treatment for ischemic stroke

1 month follow-up: physical examination, commitment treatment record, safety evaluation, vascular dementia assessment

3 month follow-up: physical examination, laboratory examination, commitment treatment record, safety evaluation, vascular dementia assessment, MMSE, MoCA, ADAS-cog, FAB evaluation

6 month follow-up: physical examination, laboratory examination, commitment treatment record, safety evaluation, vascular dementia assessment, MMSE, MoCA, ADAS-cog, FAB evaluation, MRI (optional), ASPECTS or Fazekas or CHIPS evaluation (optional)

Baseline: Evaluation within 7d after attack

Nimodipine treatment group n=328

Randomization

Cognitive Abilities Screening Instrument (CASI) test was conducted among patients experienced Acute Ischemic Stroke within 7 days to select subjects according to inclusion criteria. Each subject signed written informed consent form.

Screening

Placebo and routine treatment for ischemic stroke

Adjust sample size

Analysis on ITT population during study

Baseline: Evaluation within 7d after attack

Nimodipine (30mg,tid) and routine treatment for ischemic stroke

1 month follow-up: physical examination, commitment treatment record, safety evaluation, vascular dementia assessment

3 month follow-up: physical examination, laboratory examination, commitment treatment record, safety evaluation, vascular dementia assessment, MMSE, MoCA, ADAS-cog, FAB evaluation

6 month follow-up: physical examination, laboratory examination, commitment treatment record, safety evaluation, vascular dementia assessment, MMSE, MoCA, ADAS-cog, FAB evaluation, MRI (optional), ASPECTS or Fazekas or CHIPS evaluation (optional)